Overview

Tadalafil for the Treatment of Raynaud's

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.
Phase:
N/A
Details
Lead Sponsor:
Northwestern University
Collaborator:
Eli Lilly and Company
Treatments:
Tadalafil